Source link : https://www.newshealth.biz/health-news/with-chemo-blinatumomab-boosts-dfs-in-pediatric-b-all/
SAN DIEGO — The addition of the bispecific T-cell engager blinatumomab (Blincyto) to chemotherapy greatly boosted 3-year disease-free survival (DFS) in younger pediatric patients with newly diagnosed, standard-risk B-cell acute lymphoblastic leukemia (B-ALL), in a phase 3 randomized trial. Among pediatric patients with B-ALL followed for a mean of 2.5 years (1.6-3.2 years), 718 patients […]
Author : News Health
Publish date : 2024-12-08 22:40:02
Copyright for syndicated content belongs to the linked Source.